Document is current

Article History

Received: 16 January 2024

Accepted: 1 July 2024

First Online: 13 August 2024

Declarations

:

: The present study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and had the approval of local laws and regulations. All patients provided written informed consent according to local requirements to participate prior to screening. The trial protocol and its amendments were reviewed and approved by an independent ethics committee at each participating site. The ethics committee name and affiliated institution by location are as follows: <b>China:</b> 1) Ethics Review Board of Beijing Cancer Hospital of Peking University (Beijing Cancer Hospital of Peking University), 2) Ethics Review Board of Harbin Medical University Cancer Hospital (Harbin Medical University Cancer Hospital), and 3) Ethics Review Board of Eastern Theater General Hospital, Qinhuai District Medical Area (Eastern Theater General Hospital, Qinhuai District Medical Area); <b>South Korea:</b> 1) Samsung Medical Center Ethics Review Board (Samsung Medical Center), 2) Seoul National University College of Medicine/Seoul National University Hospital Medical Research Ethics Review Board (Seoul National University Hospital), and 3) Asan Medical Center Ethics Review Board (Asan Medical Center); <b>Taiwan:</b> 1) National Cheng Kung University Hospital Human Research Ethics Review Board (National Cheng Kung University Hospital), 2) Chi Mei Medical Center Human Research Ethics Review Board (Chi Mei Medical Center – Yong Kang Branch), 3) Chang Gung Medical Foundation Human Research Ethics Review Board (Chang Gung Medical Foundation), and 4) Chi Mei Medical Center Human Research Ethics Review Board (Chi Mei Medical Center – Liu Ying Branch).

: Not applicable.

: J.O. Park reports research grants from BMS, Servier, MedPacto, Eutilex, and ABL Bio; has served as advisor to AstraZeneca, Merck Sereno, Adicet Bio, Servier, and MediRama; and personal fees from Minneamrita Therapeutics, Intocell, ABL Bio, and ImmuneOncia. Y.H. Feng has served as an advisor to Roche, Pfizer, Johnson & Johnson, and Lotus Pharmaceutical. D.Y. Oh reports research grants from AstraZeneca, Novartis, Array BioPharma, Eli Lilly, Servier, BeiGene, MSD, and Handok; and has served as advisor to AstraZeneca, Novartis, Genentech, Roche, Merck Serono, Bayer, Taiho Pharmaceutical, Aslan Pharmaceuticals, Halozyme Therapeutics, Zymeworks Inc., BMS, Celgene, BeiGene, Basilea Pharmaceutica AG, Turning Point Therapeutics, Yuhan Corporation, Arcus Biosciences, and IQVIA. B. Keam reports research grants from MSD, Ono Pharmaceutical, and AstraZeneca; and personal fees for Handok, ImmuneOncia, Trial Informatics, CBS Bioscience, and NeoImmuneTech. L. Shen reports research grants from Beigene and participates on the data and safety monitoring board or advisory board for MSD, Boehringer Ingelheim, Servier, Merck Sereno, AstraZeneca, and Transcenta Holding Limited. S.W. Kim reports a research grant from Yuhan Corporation; has served as an advisor to Amgen and Therapex; and personal fees for Therapex. H. Liao is an employee and has stocks or other ownership in Johnson & Johnson. M. Qing is an employee and has stocks in Johnson & Johnson. C. Zhang is an employee of Johnson & Johnson. J. Qian is an employee of Johnson & Johnson. X. Tang is an employee of Johnson & Johnson. P. Li is an employee of Johnson & Johnson. S. Triantos is an employee and has stocks in Johnson & Johnson. H. Sweiti is an employee of Johnson & Johnson. The other authors (W.C. Su and X. Liu) declare to have no competing interests.